The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: Early-phase evaluation.
F. Navid
No relevant relationships to disclose
R. C. Barfield
No relevant relationships to disclose
R. Handgretinger
No relevant relationships to disclose
P. M. Sondel
No relevant relationships to disclose
B. L. Shulkin
No relevant relationships to disclose
R. Kaufman
No relevant relationships to disclose
C. Billups
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
W. L. Furman
No relevant relationships to disclose
L. M. McGregor
No relevant relationships to disclose
M. Otto
No relevant relationships to disclose
S. Gillies
No relevant relationships to disclose
V. M. Santana
No relevant relationships to disclose